IGF2BP1 and cancer: BTYNB, as a novel inhibitor of IGF2BP1, inhibits cell cycle and cancer progression by impairing IGF2BP1-dependent mRNA coding factor stability (Mahapatra et al., 2017; Muller et al., 2020).